The FDA will require manufacturers of GLP-1 drugs, including Novo Nordisk and Eli Lilly, to add safety warnings to their obesity and diabetes treatments regarding a rare eye condition called non-arteritic anterior ischemic optic neuropathy (NAION), which can cause permanent vision loss. The decision follows a review of adverse-event reports and a meta-analysis of 126 clinical trials involving more than 134,000 patients. Researchers identified 6.4 NAION cases per 100,000 patient-years among GLP-1 users, compared with 3.8 cases in control groups. A separate FDA Sentinel study found a 43% higher risk compared with DPP-4 inhibitors, although no statistically significant difference was found versus SGLT-2 inhibitors. The warning adds to growing clinical and legal scrutiny surrounding semaglutide and tirzepatide. $NVO $LLY